IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)
IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy
Fondation Ophtalmologique Adolphe de Rothschild
1,200 participants
Feb 23, 2023
OBSERVATIONAL
Conditions
Summary
IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 and 12 months of AIC treatment.
Eligibility
Inclusion Criteria5
- Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed,
- Having received informed information about the study and having signed a consent to participate in the study (if this is not possible: information and consent of the trusted support person or family member if present; emergency inclusion if absent);
- Affiliated or beneficiary of a social security scheme or equivalent.
- Pregnant or breast-feeding women
- Patient benefiting from a legal protection measure
Exclusion Criteria1
- None.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04663399